Quince Therapeutics (QNCX) Total Debt (2023 - 2025)

Quince Therapeutics has reported Total Debt for 3 years, with the latest figure at $18.0 million in Q4 2025.

• On a quarterly basis, Total Debt rose 25.87% year-over-year to $18.0 million in Q4 2025; TTM through Dec 2025 was $18.0 million, a 25.87% increase from a year earlier, with the FY2025 full-year figure at $18.0 million, up 25.87% from the prior year.
• Total Debt was $18.0 million for Q4 2025 at Quince Therapeutics, up from $17.5 million in the prior quarter.
• The five-year high for Total Debt was $18.8 million in Q2 2024, with the low at $14.3 million in Q4 2024.
• Average Total Debt over 3 years is $16.9 million, with a median of $17.5 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Total Debt decreased 18.32% in 2024, then advanced 25.87% in 2025.
• Over 3 years, Total Debt stood at $17.5 million in 2023, then fell by 18.32% to $14.3 million in 2024, then gained by 25.87% to $18.0 million in 2025.
• The last three Total Debt figures came in at $18.0 million (Q4 2025), $17.5 million (Q3 2025), and $17.0 million (Q2 2025), per Business Quant data.